Professor Jonathan Williams, one of the UK’s leading organic chemists, has received a Royal Society Wolfson Merit Award for his research.
Williams, from the University of Bath’s Department of Chemistry, is the recipient of a £10,000 a year award over a five-year period. The award will fund his research group’s work in designing metal catalysts for new chemical reactions.
In many cases, the metal catalysts developed by the group allow reactions to be more environmentally friendly because molecules can be constructed more efficiently and use less energy.
Professor Paul Raithby, Head of the Department of Chemistry, said: ‘Jonathan is undoubtedly one of the most creative and productive organic chemists of his generation in the UK. His work has influenced academic chemistry internationally, as well as having had significant impact in industrial practice.
‘Jonathan has attracted a talented group of organic chemists to Bath and we are determined to support him in further developing the department’s international reputation as a leading centre for catalysis and chemical synthesis. This award is a significant contribution to that goal.’
Until recently, the research group worked on a method of constructing chemical bonds using catalytic reactions that they termed ‘Borrowing Hydrogen Methodology’. This focused on the metal catalyst temporarily removing hydrogen from the starting material, allowing it to react more easily.
Williams said: ‘The resulting compounds from this technique are made more cleanly than they would be traditionally. Using our methodology, the only by-product created is water, and there is no need to use carcinogenic starting materials.’
The group has since changed its focus and the Wolfson Merit Award will fund research into new catalytic reactions.
‘We’re now focusing on developing new approaches to the formation of amides, the chemical bonds found in proteins, in many drug molecules, and in robust materials such as Nylon and Kevlar,’ said Williams.
‘This new research will aim to identify catalytic methods for the formation of amides, which are traditionally prepared using cumbersome, inefficient chemistry.’
Bath professor receives Wolfson Merit Award
The award will fund Jonathan Williams\' research into metal catalysts for new chemical reactions
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development
VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development
The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies
Research & Development
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
The pair will advance their strategic partnership to the next phase of clinical trials for Brainomix's e-Lung after strong initial results demonstrated its potential to enable earlier diagnosis of progressive pulmonary fibrosis